Company Overview and News

2
Retirees: Earn 7% With Preferred Stocks And Income Securities

2018-09-10 seekingalpha
Individuals who are considering retirement will need a steady stream of income to cover monthly living expenses.
SACH CLI

2
CLI / Mack-Cali Realty Corp. 8-K (Current Report)

2018-08-31 sec.gov
UNITED STATES<
CLI

2
CLI / Mack-Cali Realty Corp. 8-K (Current Report)

2018-08-31 sec.gov
UNITED STATES<
CLI

2
Mack-Cali (CLI) Up 13.6% Since Last Earnings Report: Can It Continue?

2018-08-31 zacks
It has been about a month since the last earnings report for Mack-Cali Realty (CLI - Free Report) . Shares have added about 13.6% in that time frame, outperforming the S&P 500.
CLI AR

2
Mack-Cali Realty (CLI) in Focus: Stock Moves 6.4% Higher

2018-08-16 zacks
Mack-Cali Realty Corporation (CLI - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $19.07 to $19.81 in the past one month time frame.
CLI OUT

2
Outfront Media (OUT) Q2 FFO and Revenues Miss Estimates

2018-08-09 zacks
Outfront Media, Inc. (OUT - Free Report) reported second-quarter 2018 adjusted funds from operations (FFO) per share of 55 cents, missing the Zacks Consensus Estimate of 57 cents. Further, the figure came in lower than the year-ago tally of 56 cents. The company’s results reflect lower transit and other revenues resulting from dreary environment in national advertising. Further, the revenue figure missed the Consensus mark.
GD CUZ HIW ZTO CLI OUT

2
Lamar Advertising (LAMR) Q2 Revenues Beat Estimates, FFO Up

2018-08-09 zacks
Lamar Advertising Company (LAMR - Free Report) reported second-quarter 2018 adjusted funds from operations (FFO) of $1.52 per share, marking a 9.4% increase from the year-ago tally of $1.39 per share. Results were primarily driven by growth in revenues. Same-unit digital revenues increased 6.3% during the quarter. Net revenues for the quarter climbed 5.7% from the prior-year quarter to $419.8 million.
GD CUZ HIW ZTO CLI

12
Mack-Cali Realty Corp. (CLI) CEO Michael DeMarco on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Mack-Cali Realty Corp. (NYSE:CLI) Q2 2018 Results Earnings Conference Call August 2, 2018 10:00 AM ET
LTM CLI

2
Mack-Cali (CLI) Q2 FFO Falls, Revenues Miss, Stock Down 2.8%

2018-08-03 zacks
Shares of Mack-Cali Realty Corp (CLI - Free Report) lost nearly 2.8% in the succeeding day following the release of its second-quarter results. Investors were discouraged by a 22.2% year-over-year decline in the company’s reported revenues of $126.6 million. Further, the figure missed the Zacks Consensus Estimate of $131 million. Mack-Cali’s core funds from operations (FFO) per share of 45 cents came in lower than the year-ago figure of 60 cents.
CXW MDQZZ MGP CLI MRT

2
CLI / Mack-Cali Realty Corp. 10-Q (Quarterly Report)

2018-08-01 sec.gov
Table of Contents
CLI

2
CLI / Mack-Cali Realty Corp. 10-Q (Quarterly Report)

2018-08-01 sec.gov
Table of Contents
CLI

2
CLI / Mack-Cali Realty Corp. 8-K (Current Report)

2018-08-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISS
CLI

19
Options Traders Expect Huge Moves in Mack-Cali (CLI) Stock

2018-07-18 zacks
Investors in Mack-Cali Realty Corporation (CLI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $17.50 Call had some of the highest implied volatility of all equity options today.
OCUL JAKK FTRPR CLI FTR

3
3

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CLI / Mack-Cali Realty Corp. on message board site Silicon Investor.

Climate Change Climate Change Climate Change Severe weather events, climate change and economics Severe weather events, climate change and economics Severe weather events, climate change and economics
Hillary Rodham Clinton for President 2016 Hillary Rodham Clinton for President 2016 Hillary Rodham Clinton for President 2016 Clinuvel Pharmaceuticals Ltd Clinuvel Pharmaceuticals Ltd Clinuvel Pharmaceuticals Ltd
PRESIDENT HILLARY RODHAM CLINTON PRESIDENT HILLARY RODHAM CLINTON PRESIDENT HILLARY RODHAM CLINTON The Obama - Clinton Disaster The Obama - Clinton Disaster The Obama - Clinton Disaster
Bridging weather and climate Bridging weather and climate Bridging weather and climate Hillary Clinton 2016 Hillary Clinton 2016 Hillary Clinton 2016
Clifton Mining (CFB-Alberta)-Silver Play Clifton Mining (CFB-Alberta)-Silver Play Clifton Mining (CFB-Alberta)-Silver Play The Climate Matrix The Climate Matrix The Climate Matrix
CUSIP: 554489104